Learn More
BACKGROUND The incidence of rectal cancer in the United States in young patients is considered to be low. Underestimating this incidence may result in a failure to diagnose younger patients with rectal cancer in a timely manner. METHODS The authors conducted a retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) cancer(More)
BACKGROUND The GI Mentor is a virtual reality simulator that uses force feedback technology to create a realistic training experience. OBJECTIVE To define the benefit of training on the GI Mentor on competency acquisition in colonoscopy. DESIGN Randomized, controlled, blinded, multicenter trial. SETTING Academic medical centers with accredited(More)
The PathfinderTG biomarker panel is useful in the evaluation of pancreatic cysts that have clinical features suspicious for malignancy, but its utility in classifying fine-needle aspiration biopsies from small pancreatic cystic lesions is yet to be proven. We used morphology to classify 20 pancreatic cyst cytology aspirates, all of which met radiographic(More)
BACKGROUND & AIMS Gastroesophageal reflux disease (GERD) is a common and costly disorder. Symptoms attributed to GERD have a wide spectrum of presentations and complications that have led to complex diagnostic and management algorithms. As such, there is considerable variation in clinical approaches to GERD. In contrast to multiple published guidelines for(More)
Gastrointestinal (GI) problems are a common occurrence in the critically ill cancer patient. These GI complications are often not related to the underlying cancer, but mimic the GI problems seen in noncancer patients. Common GI disorders such as peptic ulcer disease, gastritis, diverticulitis, and alcohol-related liver disease are often the underlying(More)
BACKGROUND Although screening for colorectal cancer (CRC) is a widely accepted concept nationally and screening rates are increasing, there are differences in screening rates between states and within states. METHODS In an effort to increase screening rates and ensure equal access with respect to race/ethnicity, the New York City Department of Health and(More)
14040 Background: We are conducting a phase II trial of the proteasome inhibitor, PS-341, with or without irinotecan in pts with AGA. The combination of PS-341 and irinotecan has been studied in preclinical tumor models including a murine xenograft model of colon cancer, where the combination achieved significantly more tumor shrinkage than either agent(More)
PURPOSE To determine the effectiveness of bortezomib plus irinotecan and bortezomib alone in patients with advanced gastroesophageal junction (GEJ) and gastric adenocarcinoma. We also sought to explore the effect of these therapeutics on tumor and normal gene expression in vivo. METHODS Forty-one patients with advanced GEJ (89 %) or gastric (11 %)(More)
This study was conducted to determine the safety and efficacy of the green tea-derived Polyphenon E (Poly E) in patients with Barrett's Esophagus (BE). Subjects were randomized to a 6-month, twice daily (BID) oral treatment of placebo or Poly E (200, 400, or 600 mg). Endoscopic evaluation, including biopsies, was performed before and after treatment. The(More)